Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

THE WOODLANDS, Texas, Nov. 1, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2011.

"Recent positive results from clinical studies of LX4211 and LX1032 have provided further validation for the unique mechanisms of action of these first-in-class drugs," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "We are progressing with plans to partner LX1032 on the strength of our Phase 2 data in carcinoid syndrome, and are engaged in active discussions with multiple parties about the program."

Progress in Clinical Pipeline

  • Telotristat etiprate (LX1032):  Results from the recently-completed placebo-controlled Phase 2 clinical trial of telotristat etiprate in carcinoid syndrome patients were reported at the annual meeting of the North American Neuroendocrine Tumor Society.  Telotristat etiprate, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels, showed evidence of efficacy across several endpoints, including observed reductions in bowel movement frequency; decreased urinary 5-HIAA, a biomarker of serotonin synthesis; and improvements in patient-reported relief of symptoms.  Also reported were preliminary data from an ongoing open-label Phase 2 trial, which indicate that telotristat etiprate is producing biochemical and clinical benefits, including improvements in bowel movement frequency, flushing episode frequency, urinary 5-HI
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
    2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
    3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
    4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
    5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
    6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
    7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
    8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
    9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
    10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
    11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
    (Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
    (Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
    Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
    ... 4, 2011 Reportlinker.com announces that a new ... European Market for Cardiac Rhythm ... http://www.reportlinker.com/p0488652/European-Market-for-Cardiac-Rhythm-Management-Electrophysiology--Ablation-Devices-2011.html European Market ... 2011 (15 countries) In 2010, ...
    ... 2011 Reportlinker.com announces that a ... in its catalogue: ... – Bone Grafting and Hyaluronic Acid ... http://www.reportlinker.com/p0488653/European-Markets-for-Orthopedic-Biomaterials-2011-–-Bone-Grafting-and-Hyaluronic-Acid-Viscosupplementation-15-Countries.html The ...
    Cached Medicine Technology:Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 2Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 3Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 4Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 5Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 6Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 7Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 8Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 9Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 10Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 11Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 12Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 13Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 14Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 15Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 16Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 17Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 18Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 19Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 20Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 21Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 2Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 3Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 4Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 5Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 6Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 7Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 8Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 9Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 10Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 11Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 12Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 13Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 14Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 15Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 16
    (Date:7/13/2014)... By Serena Gordon ... -- A new type of sensor for people with ... body using saliva instead of blood, researchers report. Scientists ... successfully tested it using artificial saliva. It uses light, metal ... blood sugar. "Everybody knows that diabetics have to prick ...
    (Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
    (Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
    (Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
    (Date:7/13/2014)... 2014 Hope Palliative & Hospice Care announced ... group at the Tamarack Senior Living Community in Palatine, IL. ... A.M. on the 3rd Wednesdays of every month. This ... Tamarack Community located at 55 S. Greeley St. Palatine, IL ... there is no cost for the group. , “A ...
    Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
    ... drug to the usual three-drug HIV treatment regimen is not ... the HIV load// or the drug resistance, the new study ... JAMA, a theme issue on HIV/AIDS. ,Roy M. ... New York, presented the findings of the study today at ...
    ... used HIV treatments, researchers found one triple-drug therapy was ... the blood when used as a first-line treatment. Results ... among three different therapies the optimal approach for patients ... reported at the XVI International AIDS Conference (AIDS 2006). ...
    ... new study published in the September 15, 2006 issue ... Society, says that African-Americans are least likely to// ask ... says that the level of interest displayed by Caucasian ... This fact may lead to the African-Americans making less-informed ...
    ... has said that better quality drugs and child medication ... ,Speaking to Agence France-Presse (AFP) ... in Toronto he said, "We definitely need to improve ... talking to pharmaceuticals. We definitely want to buy second-line ...
    ... radical changes in business with tangible growth in Asian countries, ... of a jet setting pace, so much a part of ... a demographic crisis, with a rampant spread of mental health ... palpable, and is attributed to the high stress in the ...
    ... in on a weakened scout cell, which is known to ... out that cancer in some of the transplant patients shows ... for the immune system. Researchers are optimistic that by ... find ways to prevent the onset of cancer. The reason ...
    Cached Medicine News:Health News:Four-Drug AIDS Treatment Regimen Deemed Of No Use 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 3Health News:Study Compares First-Line Drug Therapies For Treating HIV 4Health News:African-Americans Pose Less Questions To Treating Doctors 2Health News:Need for Newer AIDS Drugs In China 2
    Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
    ...
    Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
    Universal, clear, lightweight plastic with smooth edges & ventilation holes for patient comfort...
    Medicine Products: